BioMarin Pharmaceutical Inc.

As of June 30, 2026, BioMarin Pharmaceutical Inc. carries a market capitalization of 193.71B, placing it among publicly traded companies globally. Its enterprise value stands at 251.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioMarin Pharmaceutical Inc.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, BioMarin Pharmaceutical Inc. has 193.25M shares outstanding.

As of June 30, 2026, BioMarin Pharmaceutical Inc. trades at a trailing price-to-earnings ratio of 151.16. The price-to-sales ratio is 3.24, and the price-to-book ratio stands at 1.75.

As of June 30, 2026, BioMarin Pharmaceutical Inc. trades at an EV/EBITDA multiple of 47.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 96.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BioMarin Pharmaceutical Inc. trades at an EV/FCF ratio of 18.69, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 251.86B versus a market cap of 193.71B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioMarin Pharmaceutical Inc. maintains a current ratio of 2.39, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 66.47, indicating elevated leverage, while an interest coverage ratio of 3.61 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioMarin Pharmaceutical Inc. posted a return on equity (ROE) of 1.18, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.85 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.33, useful for judging operating efficiency across full business cycles. The company generates approximately 18.74M in revenue per employee across its workforce of 3,175.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.52 indicates how many times BioMarin Pharmaceutical Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioMarin Pharmaceutical Inc. recorded 1.33B in income tax expense. That works out to an effective tax rate of 51.06, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.61B, leaving 1.27B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on June 10, 2026, BioMarin Pharmaceutical Inc.'s stock has declined approximately 28.48% over the past 52 weeks.

Over the twelve months ended June 30, 2026, BioMarin Pharmaceutical Inc. generated 59.52B in revenue and converted that into 1.27B in net income, yielding earnings per share of 6.58. EBITDA reached 5.28B, while operating income came in at 2.61B.

As of June 30, 2026, BioMarin Pharmaceutical Inc. holds 15.27B in cash and equivalents against 73.42B in total debt, resulting in a net debt position of 57.87B. Total book value stands at 110.45B, with working capital of 40.32B providing operational flexibility.

BioMarin Pharmaceutical Inc. produced 14.97B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.21B in capital expenditures, free cash flow totaled 12.76B - equivalent to 66.39 per share.

Over the twelve months ended June 30, 2026, BioMarin Pharmaceutical Inc. posted a gross margin of 76.12, reflecting its pricing power and cost economics. The operating margin of 4.38 and net profit margin of 2.14 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.57, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -32.04, meaning BioMarin Pharmaceutical Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, BioMarin Pharmaceutical Inc. has an Altman Z-Score of 2.38, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.